Skip to Content

Stephanie Mehlis , MD

Director, Dermatology Clinical Trials Unit
Clinical Assistant Professor, University of Chicago Pritzker School of Medicine
Division of Dermatology
Department of Medicine

Contact Information

 847.663.8536 Fax


  • Medical School: 
    • Case Western Reserve School of Medicine, 1997 
    • Northwestern Feinberg School of Medicine, 2001 
  • Internship: .
    • McGaw Medical Center of Northwestern University, 2002 

  • Residency: 
    • Northwestern Feinberg School of Medicine, 2006 

  • Fellowship: 
    • Northwestern Feinberg School of Medicine, 2003 

Board Certification

  • Dermatology

Research and Academic Interests

  • Research Assistant.  Department of Photobiology, St. Thomas’ Hospital, London, UK, 1998. 
  • Research Assistant.  Department of Dermatology, Northwestern University, 2000- 2001. 
  • Clinical Trials Fellow.  Department of Dermatology, Clinical Trials Unit, Northwestern University,2002- 2003. 
  • Director Clinical Research.  NorthShore University HealthSystems.  2007 – present.

Honors and Awards

  • Cum Laude, Northwestern University, Class of 1997

  •  Crile Fellowship, CaseWestern ReserveUniversity, 1998

Scholarly Work


  1. Novakovic L, Lee S, Orchard GE, Sheehan JM, Young AR, Walker SL. Effects of solar simulated radiation dose fractionation on CD1a+ Langerhans cells and CD11b+ macrophages in human skin. Br J Dermatol 2001;145:237244.

  2.  Mehlis SL, Gordon KB. The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol 2003;49:S44–S50.

  3.  Mehlis S, Gordon KB. From laboratory to clinic: rationale for biologic therapy. Derm Clinics 2004;22:371-377.

  4.  Alwawi EA,  Mehlis SL, Gordon KB.  Treating psoriasis with adalimumab.  Ther Clin Risk Manag 2008:2:345-351.

  5.  Pathria JCollyer JMehlis SBrieva J. Pruritic, papular eruption, and concomitant neurologic symptoms: Churg-Strauss syndrome presenting with mononeuritis multiplex. Skinmed. 2010:8(2):111-2.

  6.  Gottlieb AB, Leonardi C, Kerdel F, Mehlis S, Olds M, Williams DA. Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol. 2011 May 17.

  7.  Blauvelt A, Prinz JC, Gottlieb AB, Kingo K, Sofen H, Ruer-Mulard M, Singh V, Pathan R, Papavassilis C, Cooper S; FEATURE Study Group. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015 Feb;172(2):484-93

  8. Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K; UNCOVER-2 and UNCOVER-3 investigators. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.  Lancet. 2015 Aug 8;386(9993):541-51.

  9.  Mehlis, S.  Guttate Psoriasis.  In: UpToDate,   Duffin, KC and Ofori, A (Ed). 



View more results at